Drug major Lupin today said it has received final approval from the United States Food and Drug Administration (USFDA) to market Hydrocortisone Butyrate lotion, used for treatment of mild atopic dermatitis in patients 3 months of age and older, in the US market.
The approved product is a generic version of PreCision Dermatology, Inc.'s (PreCision) Locoid Lotion, 0.1 per cent, Lupin said in a BSE filing.
As per IQVIA MAT data of April 2018, Lupin said the product had annual sales of around USD 13.8 million in the US.
Shares of Lupin were trading 0.77 per cent higher at Rs 876.50 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
